<DOC>
	<DOCNO>NCT02072811</DOCNO>
	<brief_summary>In view diversity biology acute myeloid leukemia ( AML ) therapy individual patient must individualize . One tool molecular-cytogenetic stratification . It divide patient five category ( prognostic group ) : Favorable , Intermediate-1 , Intermediate-2 , Adverse Very adverse risk . After remission proceeding tailor depend prognostic determine group . Research PALG group application second line regimen CLAG CLAG-M prove high effectiveness treatment low toxicity . Considering experience PALG group , seem use schema CLAG early second induction therapy viable treatment option .</brief_summary>
	<brief_title>Role Therapy Tailored Risk Factors Treating Adult Patients ( ≤60 ) With Acute Myeloid Leukemia</brief_title>
	<detailed_description>Patients AML one 5 prognostic category base modify cytogenetic-molecular stratification ( European Leukemia Net Prognostic System - ENL ) Favorable risk ( 8 ; 21 ) ( q22 ; q22 ) ; RUNX1-RUNX1T1 inv ( 16 ) ( p13.1q22 ) ( 16 ; 16 ) ( p13.1 ; q22 ) ; CBFB-MYH11 Mutated NPM1 without FLT3-ITD ( NK ) Mutated CEBPA ( NK ) Intermediate I risk Mutated NPM1 FLT3-ITD ( NK ) Wild-type NPM1 FLT3-ITD ( NK ) Wild-type NPM1 without FLT3-ITD ( NK ) Intermediate II risk ( 9 ; 11 ) ( p22 ; q22 ) ; MLLT3-MLL cytogenic abnormality favorable adverse Adverse risk Inv ( 3 ) ( q21q26.2 ) ( 3 ; 3 ) ( q21 ; q26.2 ) ; RPN-EVI1 Very adverse risk monosomal karyotype ( MK ) : -5 del ( 5q ) ; -7 ; abnl ( 17p ) ; complex karyotype Goals : - Evaluation impact therapy tailor risk factor outcome AML patient age ≤ 60 . - Evaluation possibility improve result induction therapy use early 2nd induction patient persistent leukemic infiltration bone marrow 14th day , - Evaluation impact minimal residual disease ( MRD ) presence assess Immunophenotyping method , result treatment AML patient age ≤ 60 , - Assessing significance monitoring number leukemic stem cell ( LSC ) bone marrow peripheral blood influence clinical course outcome AML treatment , - Assessment LSC determination usefulness MRD monitoring patient AML , - Evaluation prognostic significance expression CXCR-4 surface leukemic cell impact clinical course outcome AML - try select group patient potentially would benefit use chemosensitization plerixafor , - Evaluation autologous HSCT effectiveness consolidation therapy AML patient 3 follow cytogenetic-molecular risk group : Favorable , Intermediate I , Intermediate II , - Comparison overall survive ( OS ) leukemia-free survival autologous allogeneic HSCT AML patient Intermediate I Intermediate II cytogenetic-molecular risk group ( biological randomization donor vs. donor ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Adult acute myeloid leukemia Age : ≥18 ≤ 60 Clinical condition patient allow carry induction therapy : ECOG performance status : ≤ 2 Hematopoietic Cell TransplantComorbidity Index ( HCTI ) : ≤3 Informed consent participate study ( ICF sign ) The second early induction start criterion addition list , percentage blast level &gt; 10 % 7th day . No informed consent participation study , mental illness , n't allow obtain informed consent conduct treatment accord protocol Pregnancy HIV infection Active cancer Active hepatitis virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>AML</keyword>
</DOC>